Home Page

DUBLIN, Dec. 11, 2018 /PRNewswire/ --

The "Global Pediatric Epilepsy Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.

The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures.

Increasing demand for second and third-generation AEDs

The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.

Adverse side effects and increasing social stigma

The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.

Key Players

• Eisai
• GlaxoSmithKline
• GW Pharmaceuticals
• Pfizer
• UCB

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

• Market segmentation by product
• Comparison by product
• Second-generation anti-epileptics - Market size and forecast 2018-2023
• Third-generation anti-epileptics - Market size and forecast 2018-2023
• First-generation anti-epileptics - Market size and forecast 2018-2023
• Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Eisai
• GlaxoSmithKline
• GW Pharmaceuticals
• Pfizer
• UCB

For more information about this report visit https://www.researchandmarkets.com/research/hg939k/global_pediatric?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-pediatric-epilepsy-therapeutics-markets-2019-2023---increasing-demand-for-second--third-generation-aeds-300763542.html

SOURCE Research and Markets